DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE
Pre-Launchdolutegravir, emtricitabine and tenofovir alafenamide
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three antiretroviral agents: dolutegravir (integrase strand transfer inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). The combination is indicated for treatment of HIV-1 infection in adults and adolescents. This regimen works by simultaneously blocking viral integration, reverse transcription, and nucleotide incorporation to suppress HIV replication.
Pre-Launch
Pre-launch stage indicates formation of small core launch team with potential for significant expansion upon regulatory approval and market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this product offers exposure to HIV treatment market dynamics, regulatory approval processes, and competitive brand positioning in a therapeutic area with high unmet needs. Career growth potential is significant if the product achieves regulatory approval and successful market penetration.
Brand ManagerField Sales Representative
Worked on DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.